The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

JANUARY 3, 2019

VOL. 380 NO. 1

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

Deepak L. Bhatt, M.D., M.P.H., P. Gabriel Steg, M.D., Michael Miller, M.D., Eliot A. Brinton, M.D., Terry A. Jacobson, M.D., Steven B. Ketchum, Ph.D., Ralph T. Doyle, Jr., B.A., Rebecca A. Juliano, Ph.D., Lixia Jiao, Ph.D., Craig Granowitz, M.D., Ph.D., Jean-Claude Tardif, M.D., and Christie M. Ballantyne, M.D., for the REDUCE-IT Investigators*

ABSTRACT

BACKGROUND

Patients with elevated triglyceride levels are at increased risk for ischemic events. Icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowers triglyceride levels, but data are needed to determine its effects on ischemic events.

METHODS

We performed a multicenter, randomized, double-blind, placebo-controlled trial involving patients with established cardiovascular disease or with diabetes and other risk factors, who had been receiving statin therapy and who had a fasting triglyceride level of 135 to 499 mg per deciliter (1.52 to 5.63 mmol per liter) and a low-density lipoprotein cholesterol level of 41 to 100 mg per deciliter (1.06 to 2.59 mmol per liter). The patients were randomly assigned to receive 2 g of icosapent ethyl twice daily (total daily dose, 4 g) or placebo. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina. The key secondary end point was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.

RESULTS

A total of 8179 patients were enrolled (70.7% for secondary prevention of cardiovascular events) and were followed for a median of 4.9 years. A primary end-point event occurred in 17.2% of the patients in the icosapent ethyl group, as compared with 22.0% of the patients in the placebo group (hazard ratio, 0.75; 95% confidence interval [CI], 0.68 to 0.83; P<0.001); the corresponding rates of the key secondary end point were 11.2% and 14.8% (hazard ratio, 0.74; 95% CI, 0.65 to 0.83; P<0.001). The rates of additional ischemic end points, as assessed according to a prespecified hierarchical schema, were significantly lower in the icosapent ethyl group than in the placebo group, including the rate of cardiovascular death (4.3% vs. 5.2%; hazard ratio, 0.80; 95% CI, 0.66 to 0.98; P=0.03). A larger percentage of patients in the icosapent ethyl group than in the placebo group were hospitalized for atrial fibrillation or flutter (3.1% vs. 2.1%, P=0.004). Serious bleeding events occurred in 2.7% of the patients in the icosapent ethyl group and in 2.1% in the placebo group (P=0.06).

CONCLUSIONS

Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 g of icosapent ethyl twice daily than among those who received placebo. (Funded by Amarin Pharma; REDUCE-IT ClinicalTrials.gov number, NCT01492361.)

From Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B.); FACT (French Alliance for Cardiovascular Trials), Département Hospitalo-Universitaire FIRE (Fibrose, Inflammation, and Remodeling), Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Université Paris-Diderot, INSERM Unité 1148, Paris (P.G.S.); National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the Department of Medicine, University of Maryland School of Medicine, Baltimore (M.M.); the Utah Lipid Center, Salt Lake City (E.A.B.); the Office of Health Promotion and Disease Prevention, Department of Medicine, Emory University School of Medicine, Atlanta (T.A.J.); Amarin Pharma, Bedminster, NJ (S.B.K., R.T.D.J., R.A.J., L.J., C.G.); Montreal Heart Institute, Université de Montréal, Montreal (J.-C.T.); and the Department of Medicine, Baylor College of Medicine, and the Center for Cardiovascular Disease Prevention, Methodist De-Bakey Heart and Vascular Center, Houston (C.M.B.). Address reprint requests to Dr. Bhatt at Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, 75 Francis St., Boston, MA 02115, or at dlbhattmd@post.harvard.edu.

*A complete list of the REDUCE-IT trial investigators is provided in the Supplementary Appendix, available at NEJM.org.

This article was published on November 10, 2018, and updated on November 12, 2018, at NEJM.org.

N Engl J Med 2019;380:11-22. DOI: 10.1056/NEJMoa1812792 Copyright © 2018 Massachusetts Medical Society.

N ENGLJ MED 380;1 NEJM.ORG JANUARY 3, 2019

11

The New England Journal of Medicine

Downloaded from nejm.org at Pfizer Information & Library Sciences on August 19, 2021. For personal use only. No other uses without permission.

A Quick Take is available at NEJM.org

MONG PATIENTS WITH CARDIOVASCULAR risk factors who are receiving treatment for secondary or primary prevention, the rates of cardiovascular events remain high.1-3 Even in patients receiving appropriate treatment with statins, a substantial residual cardiovascular risk remains.⁴ In such patients, an elevated triglyceride level serves as an independent marker for an increased risk of ischemic events, as shown in epidemiologic and mendelian randomization studies.5-9 In randomized trials, medications that reduce triglyceride levels, such as extended-release niacin and fibrates, have not reduced the rates of cardiovascular events when administered in addition to appropriate medical therapy, including statins.¹⁰ Contemporary trials and recent metaanalyses of n-3 fatty acid products have not shown a benefit in patients receiving statin therapy.¹¹⁻¹³

In the Japan EPA Lipid Intervention Study (JELIS), 18,645 Japanese patients with hypercholesterolemia were randomly assigned to receive either low-intensity statin therapy plus 1.8 g of eicosapentaenoic acid (EPA) daily or statin therapy alone (there was no placebo group). The risk of major coronary events was significantly lower, by 19%, in the group that received EPA plus statin therapy than in the group that received statin therapy alone.¹⁴

These considerations led to the design of the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT).15 Icosapent ethyl is a highly purified and stable EPA ethyl ester that has been shown to lower triglyceride levels and is used as an adjunct to diet in adult patients who have triglyceride levels of at least 500 mg per deciliter (5.64 mmol per liter).^{16,17} In addition, icosapent ethyl may have antiinflammatory, antioxidative, plaque-stabilizing, and membrane-stabilizing properties.¹⁸⁻²¹ We hypothesized that the risk of cardiovascular events would be lower with icosapent ethyl therapy than with placebo among patients in whom elevated triglyceride levels served as a marker of residual risk despite statin therapy.

METHODS

TRIAL DESIGN

The design of REDUCE-IT has been published previously.¹⁵ In brief, REDUCE-IT was a phase 3b randomized, double-blind, placebo-controlled trial comparing icosapent ethyl (2 g twice daily with food [total daily dose, 4 g]) with a placebo that

contains mineral oil to mimic the color and consistency of icosapent ethyl. Randomization was stratified according to cardiovascular risk stratum (secondary-prevention cohort or primaryprevention cohort, with primary prevention capped at 30% of enrolled patients), use or no use of ezetimibe, and geographic region. Further details of the study design are provided in Figure S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org. Patients were enrolled and followed at 473 participating sites in 11 countries. The first patient underwent randomization on November 28, 2011, and the last on August 4, 2016.

The trial was sponsored by Amarin Pharma. The steering committee, which consisted of academic physicians (see the Supplementary Appendix), and representatives of the sponsor developed the protocol, available at NEJM.org, and were responsible for the conduct and oversight of the study, as well as the interpretation of the data. The sponsor was responsible for the collection and management of the data. The protocol was approved by the relevant health authorities, institutional review boards, and ethics committees. All the data analyses were performed by the sponsor, and the primary, secondary, and tertiary adjudicated end-point analyses were validated by an independent statistician from the data and safety monitoring committee. The first author vouches for the completeness and accuracy of the data and analyses and for the fidelity of the trial to the protocol.

ELIGIBILITY

Patients could be enrolled if they were 45 years of age or older and had established cardiovascular disease or were 50 years of age or older and had diabetes mellitus and at least one additional risk factor. Eligible patients had a fasting triglyceride level of 150 to 499 mg per deciliter (1.69 to 5.63 mmol per liter) and a low-density lipoprotein (LDL) cholesterol level of 41 to 100 mg per deciliter (1.06 to 2.59 mmol per liter) and had been receiving a stable dose of a statin for at least 4 weeks; because of the intraindividual variability of triglyceride levels, the initial protocol allowed for a 10% lower triglyceride level from the target lower limit, which permitted patients to be enrolled if they had a triglyceride level of at least 135 mg per deciliter (1.52 mmol per liter). The first protocol amendment in May 2013 changed the lower limit of the acceptable triglyceride level

N ENGLJ MED 380;1 NEJM.ORG JANUARY 3, 2019

The New England Journal of Medicine

Downloaded from nejm.org at Pfizer Information & Library Sciences on August 19, 2021. For personal use only. No other uses without permission.

from 150 mg per deciliter to 200 mg per deciliter (2.26 mmol per liter), with no allowance for variability. Patients were excluded if they had severe heart failure, active severe liver disease, a glycated hemoglobin level greater than 10.0%, a planned coronary intervention or surgery, a history of acute or chronic pancreatitis, or known hypersensitivity to fish, shellfish, or ingredients of icosapent ethyl or placebo. Further details regarding inclusion and exclusion criteria are provided in Tables S1 and S2 in the Supplementary Appendix. Written informed consent was obtained from all patients.

END POINTS

The primary efficacy end point was a composite of cardiovascular death, nonfatal myocardial infarction (including silent myocardial infarction), nonfatal stroke, coronary revascularization, or unstable angina in a time-to-event analysis. While the steering committee and the sponsor remained unaware of the trial-group assignments, a second protocol amendment in July 2016 designated the key secondary end point as a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in a time-to-event analysis. After the primary efficacy end-point analysis was performed, the prespecified secondary efficacy end points were examined in a hierarchical fashion in the following order: the key secondary efficacy end point; a composite of cardiovascular death or nonfatal myocardial infarction; fatal or nonfatal myocardial infarction; emergency or urgent revascularization; cardiovascular death; hospitalization for unstable angina; fatal or nonfatal stroke; a composite of death from any cause, nonfatal myocardial infarction, or nonfatal stroke; and death from any cause. Prespecified tertiary end points are listed in the Supplementary Appendix. Adjudication of all the above events was performed by an independent clinical end-point committee whose members were unaware of the trial-group assignments and lipid levels.

STATISTICAL ANALYSIS

In this event-driven trial, it was estimated that approximately 1612 adjudicated primary end-point events would be necessary to provide the trial with 90% power to detect a 15% lower risk of the primary composite end point in the icosapent ethyl group than in the placebo group. We estimated that a sample size of approximately 7990 patients would be required to reach that number of primary end-point events. The primary efficacy analysis was based on the time from randomization to the first occurrence of any component of the primary composite end point. If the risk of the primary composite end point was significantly lower with icosapent ethyl than with placebo at a final two-sided alpha level of 0.0437 (as determined with the use of O'Brien-Fleming boundaries generated with the Lan-DeMets alphaspending function approach after accounting for two prespecified interim efficacy analyses), the key secondary end point and other prespecified secondary end points were to be tested in a hierarchical fashion at the same final alpha level of 0.0437. All analyses were performed according to the intention-to-treat principle. Hazard ratios and 95% confidence intervals were generated with the use of a Cox proportional-hazards model that included trial-group assignment as a covariate, stratified according to cardiovascular risk category, geographic region, and use of ezetimibe. Log-rank P values from a Kaplan-Meier analysis that was stratified according to the three randomization factors are reported to evaluate the timing of events in the two trial groups. With respect to the tertiary and subgroup efficacy analyses, 95% confidence intervals (which were not adjusted for multiple comparisons) are reported. An independent data and safety monitoring committee oversaw the study and performed two prespecified interim efficacy reviews.

RESULTS

PATIENTS

A total of 19,212 patients were screened, of whom 8179 (43%) underwent randomization. At the time of database lock, vital status was available for 99.8% of the patients; 152 patients (1.9%) did not complete the final study visits, and 578 patients (7.1%) withdrew consent. Details regarding the disposition of the patients are provided in Figure S2 in the Supplementary Appendix.

The baseline characteristics of the patients are shown in Table 1. Among the patients who underwent randomization, 70.7% were enrolled on the basis of secondary prevention (i.e., patients had established cardiovascular disease) and 29.3% on the basis of primary prevention (i.e., patients had diabetes mellitus and at least one additional risk factor). The median age of the patients was 64 years; 28.8% were female, and 38.5% were from the United States. At baseline, the median

N ENGLJ MED 380;1 NEJM.ORG JANUARY 3, 2019

13

The New England Journal of Medicine

Downloaded from nejm.org at Pfizer Information & Library Sciences on August 19, 2021. For personal use only. No other uses without permission.

Table 1. Characteristics of the Patients at Baseline.*			
Characteristic	Icosapent Ethyl (N=4089)	Placebo (N=4090)	
Age			
Median (IQR) — yr	64.0 (57.0–69.0)	64.0 (57.0–69.0)	
≥65 yr — no. (%)	1857 (45.4)	1906 (46.6)	
Male sex — no. (%)	2927 (71.6)	2895 (70.8)	
White race — no. (%)†	3691 (90.3)	3688 (90.2)	
Body-mass index:			
Median (IQR)	30.8 (27.8–34.5)	30.8 (27.9–34.7)	
≥30 — no. (%)	2331 (57.0)	2362 (57.8)	
Geographic region — no. (%)∬			
United States, Canada, the Netherlands, Australia, New Zealand, and South Africa	2906 (71.1)	2905 (71.0)	
Eastern European	1053 (25.8)	1053 (25.7)	
Asia–Pacific	130 (3.2)	132 (3.2)	
Cardiovascular risk stratum — no. (%)			
Secondary-prevention cohort	2892 (70.7)	2893 (70.7)	
Primary-prevention cohort	1197 (29.3)	1197 (29.3)	
Ezetimibe use — no. (%)	262 (6.4)	262 (6.4)	
Statin intensity — no. (%)			
Low	254 (6.2)	267 (6.5)	
Moderate	2533 (61.9)	2575 (63.0)	
High	1290 (31.5)	1226 (30.0)	
Data missing	12 (0.3)	22 (0.5)	
Diabetes — no. (%)			
Type 1	27 (0.7)	30 (0.7)	
Type 2	2367 (57.9)	2363 (57.8)	
No diabetes at baseline	1695 (41.5)	1694 (41.4)	
Data missing	0	3 (0.1)	
Median high-sensitivity CRP level (IQR) — mg/liter	2.2 (1.1-4.5)	2.1 (1.1-4.5)	
Median triglyceride level (IQR) — mg/dl	216.5 (176.5–272.0)	216.0 (175.5–274.0)	
Median HDL cholesterol level (IQR) — mg/dl	40.0 (34.5–46.0)	40.0 (35.0-46.0)	
Median LDL cholesterol level (IQR) — mg/dl	74.0 (61.5-88.0)	76.0 (63.0–89.0)	
Distribution of triglyceride levels — no./total no. (%)			
<150 mg/dl	412/4086 (10.1)	429/4089 (10.5)	
≥150 to <200 mg/dl	1193/4086 (29.2)	1191/4089 (29.1)	
≥200 mg/dl	2481/4086 (60.7)	2469/4089 (60.4)	
Triglyceride level ≥200 mg/dl and HDL cholesterol level ≤35 mg/dl — no. (%)	823 (20.1)	794 (19.4)	
Median eicosapentaenoic acid level (IQR) — μ g/ml	26.1 (17.1–40.1)	26.1 (17.1–39.9)	

* Median low-density lipoprotein (LDL) cholesterol level at baseline differed significantly between the trial groups (P=0.03); there were no other significant between-group differences in baseline characteristics. To convert the values for triglycerides to millimoles per liter, multiply by 0.01129. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. In general, the baseline value was defined as the last nonmissing measurement obtained before randomization. The baseline LDL cholesterol value as measured by means of preparative ultracentrifugation was used in our analyses; however, if the preparative ultracentrifugation value was missing, the LDL cholesterol value measured by another method was used in the following order of priority: the value obtained by means of direct measurement of LDL cholesterol, the value derived with the use of the Friedewald equation (only for patients with a triglyceride level <400 mg per deciliter), and the value derived with the use of the calculation published by Johns Hopkins University investigators.²² At the first and second screening visits, the LDL cholesterol value was obtained by means of direct measurement or preparative ultracentrifugation if at the same visit the triglyceride level was higher than 400 mg per deciliter. For all other measures of lipid and lipoprotein markers, whenever possible, the baseline value was derived as the arithmetic mean of the value obtained at visit 2 (day 0) and the value obtained at the preceding screening visit. If only one of these values was available, that single value was used as the baseline value. CRP denotes C-reactive protein, HDL high-density lipoprotein, and IQR interquartile range. Percentages may not total 100 because of rounding.

† Race was reported by the investigators.

‡ Body-mass index is the weight in kilograms divided by the square of the height in meters.

 \S Eastern European region includes Poland, Romania, Russia, and Ukraine, and Asia–Pacific region includes India.

N ENGLJ MED 380;1 NEJM.ORG JANUARY 3, 2019

The New England Journal of Medicine

Downloaded from nejm.org at Pfizer Information & Library Sciences on August 19, 2021. For personal use only. No other uses without permission.


LDL cholesterol level was 75.0 mg per deciliter (1.94 mmol per liter), the median high-density lipoprotein cholesterol level was 40.0 mg per deciliter (1.03 mmol per liter), and the median triglyceride level was 216.0 mg per deciliter (2.44 mmol per liter).²²

FOLLOW-UP AND EFFECTS ON LIPIDS

The median duration of follow-up was 4.9 years (maximum, 6.2 years). The median change in triglyceride level from baseline to 1 year was a decrease of 18.3% (-39.0 mg per deciliter [-0.44 mmol per liter]) in the icosapent ethyl group and an increase of 2.2% (4.5 mg per deciliter [0.05 mmol per liter]) in the placebo group; the median reduction from baseline (as estimated with the use of the Hodges–Lehmann approach) was 19.7% greater in the icosapent ethyl group than in the placebo group (a 44.5 mg per deciliter [0.50 mmol per liter] greater reduction; P<0.001). The median change in LDL cholesterol level from baseline was an increase of 3.1% (2.0 mg per deciliter [0.05 mmol per liter]) in the icosapent ethyl group and an increase of 10.2% (7.0 mg per deciliter [0.18 mmol per liter]) in the placebo group — a 6.6% (5.0 mg per deciliter [0.13 mmol per liter]) lower increase with icosapent ethyl than with placebo (P<0.001). The results with respect to levels of EPA and lipid, lipoprotein, and inflammatory biomarkers are provided in Table S4 in the Supplementary Appendix.

CLINICAL END POINTS

A total of 1606 adjudicated primary end-point events occurred. A primary end-point event occurred in 17.2% of the patients in the icosapent ethyl group, as compared with 22.0% of the patients in the placebo group (hazard ratio, 0.75; 95% confidence interval [CI], 0.68 to 0.83; P<0.001), an absolute between-group difference of 4.8 percentage points (95% CI, 3.1 to 6.5); the number needed to treat to avoid one primary end-point event was 21 (95% CI, 15 to 33) over a median follow-up of 4.9 years.^{23,24} The event curves based on a Kaplan-Meier analysis of the primary efficacy end point are provided in Figure 1A. The results of time-to-event analyses of each component of the primary end point are provided in Figure S3 in the Supplementary Appendix. A key secondary efficacy end-point event (Fig. 1B) occurred in 11.2% of the patients in the icosapent ethyl group, as compared with 14.8% of the patients in the placebo group (hazard ratio, 0.74;






Figure 1. Cumulative Incidence of Cardiovascular Events.

Panel A shows the Kaplan–Meier event curves for the primary efficacy composite end point of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina in the icosapent ethyl group and the placebo group, in a time-to-event analysis. Panel B shows the Kaplan–Meier event curves for the key secondary efficacy composite end point of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in the two trial groups, in a time-to-event analysis. In each panel, the inset shows the same data on an expanded y axis. The curves were visually truncated at 5.7 years because a limited number of events occurred beyond that time point; all patient data were included in the analyses.

95% CI, 0.65 to 0.83; P<0.001), corresponding to an absolute between-group difference of 3.6 percentage points (95% CI, 2.1 to 5.0); the number needed to treat to avoid one key secondary end-

N ENGLJ MED 380;1 NEJM.ORG JANUARY 3, 2019

15

The New England Journal of Medicine

Downloaded from nejm.org at Pfizer Information & Library Sciences on August 19, 2021. For personal use only. No other uses without permission.

Subgroup	Icosapent Ethyl	Placebo	Hazard Ratio (95% CI)		P Value for Interaction
•		nt/total no. of patients (%	· · · · ·		
All patients	705/4089 (17.2)	901/4090 (22.0)		0.75 (0.68-0.83)	
Risk stratum		501/1050 (1210)	_		0.14
Secondary-prevention cohort	559/2892 (19.3)	738/2893 (25.5)		0.73 (0.65-0.81)	
Primary-prevention cohort	146/1197 (12.2)	163/1197 (13.6)		0.88 (0.70–1.10)	
Region	110/1107 (12.2)	103/1137 (13.0)	_	0.00 (0.70 1.10)	0.30
United States, Canada,	551/2906 (19.0)	713/2905 (24.5)		0.74 (0.66–0.83)	0.50
the Netherlands, Australia, New Zealand, and South Africa	551/2500 (15.0)	71572905 (24.5)	-	0.74 (0.00-0.03)	
Eastern Europe	143/1053 (13.6)	167/1053 (15.9)		0.84 (0.67-1.05)	
Asia-Pacific	11/130 (8.5)	21/132 (15.9) -		0.49 (0.24-1.02)	
Ezetimibe use		, , ,			0.64
No	649/3827 (17.0)	834/3828 (21.8)		0.75 (0.67-0.83)	
Yes	56/262 (21.4)	67/262 (25.6)		0.82 (0.57-1.16)	
Sex	/ (/	, , ,		()	0.33
Male	551/2927 (18.8)	715/2895 (24.7)		0.73 (0.65-0.82)	
Female	154/1162 (13.3)	186/1195 (15.6)		0.82 (0.66-1.01)	
Race	10 1/ 1102 (1010)	100/1100 (1010)	_	0.02 (0.00 1.01)	0.18
White	646/3691 (17.5)	812/3688 (22.0)		0.77 (0.69–0.85)	0.10
Other	59/398 (14.8)	89/401 (22.2)		0.60 (0.43–0.83)	
Age	55/550 (11.0)	007101(22.2)	-	0.00 (0.15 0.05)	0.004
<65 yr	322/2232 (14.4)	460/2184 (21.1)		0.65 (0.56-0.75)	0.004
≥65 yr	383/1857 (20.6)	441/1906 (23.1)		0.87 (0.76–1.00)	
From the United States	565/1657 (20.0)	441/1900 (23.1)	-	0.87 (0.70-1.00)	0.14
Yes	201/15/0/10 2)	201/1508 (21 7)		0.69 (0.59–0.80)	0.14
No	281/1548 (18.2)	394/1598 (24.7)		()	
Diabetes at baseline	424/2541 (16.7)	507/2492 (20.3)		0.80 (0.71–0.91)	0.56
	422/2204 (10.1)	F2C (2202 (22 A)	_		0.56
Yes	433/2394 (18.1)	536/2393 (22.4)		0.77 (0.68–0.87)	
No	272/1695 (16.0)	365/1694 (21.5)		0.73 (0.62–0.85)	0.43
Baseline estimated GFR	107/005 (01.0)		_	0.73 (0.50, 0.05)	0.41
<60 ml/min/1.73 m ²	197/905 (21.8)	263/911 (28.9)		0.71 (0.59–0.85)	
≥60 to <90 ml/min/1.73 m ²	380/2217 (17.1)	468/2238 (20.9)		0.80 (0.70–0.92)	
≥90 ml/min/1.73 m ²	128/963 (13.3)	170/939 (18.1)		0.70 (0.56–0.89)	
Baseline triglycerides					0.45
≥200 mg/dl	430/2481 (17.3)	559/2469 (22.6)	-8	0.73 (0.64–0.83)	
<200 mg/dl	275/1605 (17.1)	342/1620 (21.1)		0.79 (0.67–0.93)	
Baseline triglycerides					0.83
≥150 mg/dl	640/3674 (17.4)	811/3660 (22.2)	-8-	0.75 (0.68–0.83)	
<150 mg/dl	65/412 (15.8)	90/429 (21.0)		0.79 (0.57–1.09)	
Baseline triglycerides ≥200 mg/dl and HDL cholesterol ≤35 mg/dl					0.04
Yes	149/823 (18.1)	214/794 (27.0)		0.62 (0.51–0.77)	
No	554/3258 (17.0)	687/3293 (20.9)		0.79 (0.71–0.88)	
Baseline statin intensity					0.12
High	232/1290 (18.0)	310/1226 (25.3)		0.69 (0.58–0.82)	
Moderate	424/2533 (16.7)	543/2575 (21.1)		0.76 (0.67–0.86)	
Low	48/254 (18.9)	45/267 (16.9)		1.12 (0.74–1.69)	
Baseline LDL cholesterol (derived) in thirds					0.62
≤67 mg/dl	244/1481 (16.5)	302/1386 (21.8)		0.72 (0.61-0.85)	
>67 to ≤84 mg/dl	248/1347 (18.4)	307/1364 (22.5)		0.81 (0.68-0.96)	
>84 mg/dl	213/1258 (16.9)	292/1339 (21.8)		0.74 (0.62–0.89)	
Baseline high-sensitivity CRP					0.07
≤2 mg/liter	288/1919 (15.0)	407/1942 (21.0)		0.68 (0.58-0.79)	
>2 mg/liter	417/2167 (19.2)	494/2147 (23.0)	- 	0.81 (0.71-0.93)	
		0.2	0.6 1.0 1.4 1	.8	
		-			
		10	cosapent Ethyl Placebo Better Better		

N ENGLJ MED 380;1 NEJM.ORG JANUARY 3, 2019

The New England Journal of Medicine

Downloaded from nejm.org at Pfizer Information & Library Sciences on August 19, 2021. For personal use only. No other uses without permission.

Figure 2 (facing page). Primary Efficacy Composite End Point in Selected Prespecified Subgroups.

Shown are the hazard ratios and 95% confidence intervals for the primary efficacy composite end point of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina, as assessed in a time-to-event analysis, in selected prespecified subgroups of the intention-totreat population (all patients who underwent randomization). The confidence intervals shown for the subgroup analyses have not been adjusted for multiple testing, and inferences drawn from the intervals may not be reproducible. Race was reported by the investigators. Eastern European region includes Poland, Romania, Russia, and Ukraine, and Asia-Pacific region includes India. To convert the values for triglycerides to millimoles per liter, multiply by 0.01129. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. CRP denotes C-reactive protein, GFR glomerular filtration rate, HDL high-density lipoprotein, and LDL low-density lipoprotein. The LDL cholesterol value obtained by means of preparative ultracentrifugation was used. If the preparative ultracentrifugation value was missing, the LDL cholesterol value measured by another method was used in the following order of priority: the nonmissing value obtained by means of direct measurements of LDL cholesterol, the value derived with the use of the Friedewald equation, and the value derived with the use of the calculation published by Johns Hopkins University investigators.22

point event was 28 (95% CI, 20 to 47) over a median follow-up 4.9 years.^{23,24}

The rates of the primary and key secondary efficacy end points in selected prespecified subgroups are provided in Figures 2 and 3; the findings show a consistent benefit with icosapent ethyl. Baseline triglyceride levels (≥150 vs. <150 mg per deciliter or ≥ 200 or < 200 mg per deciliter) had no influence on the primary or key secondary efficacy end points (Figs. 2 and 3). The attainment of triglyceride levels of 150 mg per deciliter or higher or below 150 mg per deciliter at 1 year after randomization also had no influence on the efficacy of icosapent ethyl as compared with placebo with respect to the primary or key secondary efficacy end point (Fig. S4 in the Supplementary Appendix). In a post hoc analysis, we found no substantial difference in the benefit of icosapent ethyl as compared with placebo with respect to the primary end point according to whether the patients who received placebo had an increase in LDL cholesterol levels at 1 year or had no change or a decrease in LDL cholesterol levels.

points (Fig. 4), the rates of all individual and composite ischemic end points (except for death from any cause - the last secondary end point in the hierarchy) were significantly lower in the icosapent ethyl group than in the placebo group, including the rate of cardiovascular death (4.3% vs. 5.2%; hazard ratio, 0.80; 95% CI, 0.66 to 0.98; P=0.03). The rate of death from any cause was 6.7% in the icosapent ethyl group and 7.6% in the placebo group (hazard ratio, 0.87; 95% CI, 0.74 to 1.02). The results for selected prespecified tertiary end points, which were not adjusted for multiple comparisons, are provided in Table S3 in the Supplementary Appendix. Among these results, the rates of adjudicated sudden cardiac death were 1.5% in the icosapent ethyl group and 2.1% in the placebo group (hazard ratio, 0.69; 95% CI, 0.50 to 0.96), and the rates of cardiac arrest were 0.5% and 1.0%, respectively (hazard ratio, 0.52; 95% CI, 0.31 to 0.86).

SAFETY AND ADVERSE EVENTS

The overall rates of adverse events that occurred while the patients were in the trial and the rates of serious adverse events leading to discontinuation of the trial drug or placebo did not differ significantly between the trial groups (Table S5 in the Supplementary Appendix). The only serious adverse event that occurred at a frequency of at least 2% was pneumonia (2.6% in the icosapent ethyl group and 2.9% in the placebo group, P=0.42). Adverse events that occurred in at least 5% of patients are reported in Table S6 in the Supplementary Appendix. The rate of atrial fibrillation was significantly higher in the icosapent ethyl group than in the placebo group (5.3% vs. 3.9%), as was the rate of peripheral edema (6.5% vs. 5.0%), but the rate of anemia was significantly lower in the icosapent ethyl group than in the placebo group (4.7% vs. 5.8%), as were the rates of diarrhea (9.0% vs. 11.1%) and gastrointestinal adverse events (33.0% vs. 35.1%) (Table S7 in the Supplementary Appendix). The rate of the prespecified adjudicated tertiary end point of heart failure did not differ significantly between the icosapent ethyl group and the placebo group (4.1% and 4.3%, respectively). The rate of the prespecified adjudicated tertiary end point of hospitalization for atrial fibrillation or flutter was significantly higher in the icosapent ethyl group than in the placebo group (3.1% vs. 2.1%, P=0.004). In the prespecified hierarchical testing of end The overall rates of serious adverse bleeding

N ENGLJ MED 380;1 NEJM.ORG JANUARY 3, 2019

The New England Journal of Medicine

Downloaded from nejm.org at Pfizer Information & Library Sciences on August 19, 2021. For personal use only. No other uses without permission.

Subgroup	Icosapent Ethyl	Placebo	Hazard Ratio (95% CI)	P Value for Interaction
•		t/total no. of patients (%)	()	interaction
All patients	459/4089 (11.2)	606/4090 (14.8)	—— 0.74 (0.65–0.83)	
Risk stratum	1357 1005 (11.2)	000/4000 (14.0)		0.41
Secondary-prevention cohort	361/2892 (12.5)	489/2893 (16.9)	0.72 (0.63–0.82)	0111
Primary-prevention cohort	98/1197 (8.2)	117/1197 (9.8)	0.81 (0.62–1.06)	
Region				0.54
United States, Canada,	358/2906 (12.3)	473/2905 (16.3)	0.73 (0.64–0.84)	
the Netherlands, Australia, New Zealand, and South Africa	55072500 (1215)			
Eastern European	93/1053 (8.8)	117/1053 (11.1)	0.78 (0.59–1.02)	
Asia–Pacific	8/130 (6.2)	16/132 (12.1)	0.47 (0.20–1.10)	
Ezetimibe use				0.46
No	426/3827 (11.1)	569/3828 (14.9)		
Yes	33/262 (12.6)	37/262 (14.1)	0.87 (0.54–1.39)	
Sex				0.44
Male	353/2927 (12.1)	474/2895 (16.4)		
Female	106/1162 (9.1)	132/1195 (11.0)	0.80 (0.62–1.03)	
Race				0.13
White	418/3691 (11.3)	538/3688 (14.6)		
Other	41/398 (10.3)	68/401 (17.0)	0.55 (0.38–0.82)	
Age				0.06
<65 yr	200/2232 (9.0)	290/2184 (13.3)	0.65 (0.54–0.78)	
≥65 yr	259/1857 (13.9)	316/1906 (16.6)	0.82 (0.70–0.97)	
From the United States				0.38
Yes	187/1548 (12.1)	266/1598 (16.6)	0.69 (0.57–0.83)	
No	272/2541 (10.7)	340/2492 (13.6)	0.77 (0.66–0.91)	
Baseline diabetes	, , ,	, , ,		0.29
Yes	286/2394 (11.9)	391/2393 (16.3)	0.70 (0.60–0.81)	
No	173/1695 (10.2)	215/1694 (12.7)	0.80 (0.65–0.98)	
Baseline estimated GFR	, , , ,	, , ,		0.77
<60 ml/min/1.73 m ²	152/905 (16.8)	205/911 (22.5)	0.71 (0.57–0.88)	
≥60 to <90 ml/min/1.73 m ²	229/2217 (10.3)	296/2238 (13.2)	0.77 (0.64–0.91)	
≥90 ml/min/1.73 m ²	78/963 (8.1)	105/939 (11.2)	0.70 (0.52–0.94)	
Baseline triglycerides	, , ,	, , ,		0.62
≥200 mg/dl	290/2481 (11.7)	371/2469 (15.0)	0.75 (0.65–0.88)	
<200 mg/dl	169/1605 (10.5)	235/1620 (14.5)	0.71 (0.58–0.86)	
Baseline triglycerides	, , , ,	, , ,		0.68
≥150 mg/dl	421/3674 (11.5)	546/3660 (14.9)	0.74 (0.65–0.84)	
<150 mg/dl	38/412 (9.2)	60/429 (14.0)	0.66 (0.44–0.99)	
Baseline triglycerides ≥200 mg/dl an HDL cholesterol ≤35 mg/dl	d	, , ,		0.50
Yes	101/823 (12.3)	136/794 (17.1)	0.68 (0.53−0.88)	
No	356/3258 (10.9)	470/3293 (14.3)	_ 0.75 (0.65−0.86)	
Baseline statin intensity				0.10
High	151/1290 (11.7)	210/1226 (17.1)	0.66 (0.54–0.82)	
Moderate	270/2533 (10.7)	361/2575 (14.0)		
Low	37/254 (14.6)	32/267 (12.0)	▶ 1.20 (0.74–1.93)	
Baseline LDL cholesterol (derived) in thirds				0.97
≤67 mg/dl	157/1481 (10.6)	196/1386 (14.1)	—— 0.73 (0.59–0.90)	
>67 to ≤84 mg/dl	157/1347 (11.7)	208/1364 (15.2)	0.75 (0.61–0.93)	
>84 mg/dl	145/1258 (11.5)	202/1339 (15.1)	0.74 (0.60–0.91)	
Baseline hsCRP				0.97
≤2 mg/liter	183/1919 (9.5)	245/1942 (12.6)		
>2 mg/liter	276/2167 (12.7)	361/2147 (16.8)	0.73 (0.63–0.86)	
		0.2	0.6 1.0 1.4 1.8	
		•		
		lo	cosapent Ethyl Placebo Better Better	

N ENGLJ MED 380;1 NEJM.ORG JANUARY 3, 2019

The New England Journal of Medicine

Downloaded from nejm.org at Pfizer Information & Library Sciences on August 19, 2021. For personal use only. No other uses without permission.

Figure 3 (facing page). Key Secondary Efficacy Composite End Point in Selected Prespecified Subgroups.

Shown are the hazard ratios and 95% confidence intervals for the key secondary efficacy composite end point of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, as assessed in a time-toevent analysis, in selected prespecified subgroups of the intention-to-treat population. The confidence intervals shown for the subgroup analyses have not been adjusted for multiple testing, and inferences drawn from the intervals may not be reproducible.

events that occurred while the patients were in the trial were 2.7% in the icosapent ethyl group and 2.1% in the placebo group (P=0.06), although there were no fatal bleeding events in either group; there were no significant differences between the icosapent ethyl group and the placebo group in the rates of adjudicated hemorrhagic stroke (0.3% vs. 0.2%, P=0.55), serious central nervous system bleeding (0.3% vs. 0.2%, P=0.42), or gastrointestinal bleeding (1.5% vs. 1.1%, P=0.15) (Table S8 in the Supplementary Appendix).

DISCUSSION

In REDUCE-IT, the risk of the primary composite end point of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina, assessed in a time-to-event analysis, was significantly lower, by 25%, among the patients who received 2 g of icosapent ethyl twice daily than among those who received placebo, corresponding to an absolute between-group difference of 4.8 percentage points in the rate of the end point and a number needed to treat of 21. The risk of the key secondary composite end point of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in a time-to-event analysis was also significantly lower, by 26%, in the icosapent ethyl group than in the placebo group, corresponding to an absolute between-group difference of 3.6 percentage points in the rate of the end point and a number needed to treat of 28. Prespecified hierarchical testing of other secondary end points revealed that the risks of a variety of fatal and nonfatal ischemic events were lower in the icosapent ethyl group than in the placebo group, including a 20% lower risk of cardiovascular death. The benefits were observed against a background of appropriate statin use among patients who had a median LDL cholesterol level of 75.0 mg per deciliter at baseline.

The overall rates of adverse events were similar in the trial groups. Serious adverse events related to bleeding occurred in more patients in the icosapent ethyl group than in the placebo group, although the overall rates were low; there were no fatal bleeding events in either group, and the rates of adjudicated hemorrhagic stroke, serious central nervous system bleeding, and serious gastrointestinal bleeding were not significantly higher in the icosapent ethyl group than in the placebo group. The rate of hospitalization for atrial fibrillation or flutter was significantly higher in the icosapent ethyl group than in the placebo group, although the rates were low. The rates of adverse events and serious adverse events leading to discontinuation of trial drug were similar in the two groups.

The results of REDUCE-IT stand apart from the negative findings of several contemporary trials of other agents that also lower triglyceride levels, including other n-3 fatty acids, extendedrelease niacin, fenofibrate, and cholesteryl ester transfer protein inhibitors.¹⁰⁻¹³ It is not known whether the lack of benefit from n-3 fatty acids in previous trials may be attributable to the low dose or to the low ratio of EPA to docosahexaenoic acid (DHA).^{12,13} Both the formulation (a highly purified and stable EPA ethyl ester) and dose (total daily dose of 4 g) used in REDUCE-IT were different from those in previous outcome trials of n-3 fatty acids. JELIS, which compared a combination of statin therapy and pure EPA with statin therapy alone, showed that the risk of ischemic events was significantly lower in the group that received the combination treatment than in the group that received statin therapy alone.¹⁴ Although the dose of EPA administered in JELIS (1.8 g daily) was lower than the EPA-equivalent dose used in REDUCE-IT (4 g daily), it resulted in a plasma EPA level (170 μ g per milliliter in a Japanese population) similar to that attained in a previous 12-week lipid study in which a total daily dose of 4 g of icosapent ethyl was used in a Western population (183 μ g per milliliter)^{25,26} and similar to that attained in the current trial. However, unlike the current trial, JELIS included an open-label design without a placebo group, used a low-intensity statin, and was conducted in a single country; patients also had higher levels of LDL cholesterol at baseline (182 mg per

19

The New England Journal of Medicine

Downloaded from nejm.org at Pfizer Information & Library Sciences on August 19, 2021. For personal use only. No other uses without permission.

The NEW ENGLAND JOURNAL of MEDICINE

End Point	Icosapent Ethyl (N=4089)	Placebo (N=4090)	Hazard	Ratio (95% CI)		P Value
	no. of patients u	vith event (%)				
Primary composite	705 (17.2)	901 (22.0)			0.75 (0.68-0.83)	< 0.001
Key secondary composite	459 (11.2)	606 (14.8)			0.74 (0.65-0.83)	<0.001
Cardiovascular death or nonfatal myocardial infarction	392 (9.6)	507 (12.4)			0.75 (0.66–0.86)	<0.001
Fatal or nonfatal myocardial infarction	250 (6.1)	355 (8.7)			0.69 (0.58-0.81)	< 0.001
Urgent or emergency revascularization	216 (5.3)	321 (7.8)			0.65 (0.55-0.78)	< 0.001
Cardiovascular death	174 (4.3)	213 (5.2)			0.80 (0.66-0.98)	0.03
Hospitalization for unstable angina	108 (2.6)	157 (3.8)			0.68 (0.53-0.87)	0.002
Fatal or nonfatal stroke	98 (2.4)	134 (3.3)	_		0.72 (0.55-0.93)	0.01
Death from any cause, nonfatal myocardial infarction, or nonfatal stroke	549 (13.4)	690 (16.9)			0.77 (0.69–0.86)	<0.001
Death from any cause	274 (6.7)	310 (7.6) 0.4	0.6 0.8 1.0	- D 1.2 1.4	0.87 (0.74–1.02)	—
			Icosapent Ethyl Better	Placebo Better		

Figure 4. Hierarchical Testing of End Points.

Shown is the prespecified plan for hierarchical testing of end points. The rates of all end points up to death from any cause were significantly lower in the icosapent ethyl group than in the placebo group.

deciliter [4.71 mmol per liter] before initiation of statin therapy) and lower baseline triglyceride values (151 mg per deciliter [1.70 mmol per liter]) than the patients in REDUCE-IT.

Metabolic data provide evidence that icosapent ethyl–based formulations do not raise LDL cholesterol levels, whereas DHA-based formulations do.²⁷ The results of the current trial should not be generalized to other n–3 fatty acid preparations — in particular, dietary-supplement preparations of n–3 fatty acid mixtures, which are variable and unregulated and which have not been shown to have clinical benefit.

A triglyceride level of 150 mg per deciliter or higher was an initial inclusion criterion in REDUCE-IT (although the required level was subsequently changed to ≥ 200 mg per deciliter); however, owing to allowance for variability in these levels, 10.3% of enrolled patients had triglyceride levels lower than 150 mg per deciliter at baseline. The observed cardiovascular benefits were similar across baseline levels of triglycerides (<150, ≥150 to <200, and ≥200 mg per deciliter). In addition, the significantly lower risk of major adverse cardiovascular events with icosapent ethyl than with placebo appeared to occur irrespective of the attained triglyceride level at 1 year (≥150 or <150 mg per deciliter), which suggests that the cardiovascular risk reduction was not associated with attainment of a more normal triglyceride level. These observations suggest that at least some of the effect of

icosapent ethyl that resulted in a lower risk of ischemic events than that with placebo may be explained by metabolic effects other than a reduction of triglyceride levels.²⁸

Mechanisms responsible for the benefit of icosapent ethyl observed in REDUCE-IT are currently not known. The timing of the divergence of the Kaplan-Meier event curves suggests a delayed onset of benefit, which may reflect the time that is needed for a benefit from a reduction in triglyceride levels to be realized or may indicate that other mechanisms are involved. The modestly higher rate of bleeding events with icosapent ethyl suggests that there may be an antithrombotic mechanism of action. However, it is unlikely that an antithrombotic effect would reduce the rate of elective revascularization. Also, if the full explanation involved an antiplatelet or anticoagulant effect, one might expect a large increase in the rate of major bleeding events, which was not observed.²⁹ It is possible that membranestabilizing effects could explain part of the benefit.^{20,21,30} Stabilization or regression of coronary plaque (or both) may also play a part.^{19,31} Our observation of lower rates of cardiac arrest and sudden cardiac death with icosapent ethyl than with placebo in the current trial might support that mechanism, although these findings should be viewed as exploratory. It is also possible that the difference in high-sensitivity C-reactive protein level observed in REDUCE-IT may contribute to the benefit; the Canakinumab Antiinflam-

N ENGLJ MED 380;1 NEJM.ORG JANUARY 3, 2019

The New England Journal of Medicine

Downloaded from nejm.org at Pfizer Information & Library Sciences on August 19, 2021. For personal use only. No other uses without permission.

matory Thrombosis Outcome Study (CANTOS) showed a significant reduction in the risk of ischemic events with treatment targeted at in-flammation.³²⁻³⁵ Blood samples obtained during REDUCE-IT have been banked for biomarker and genetic analyses that may provide more information regarding mechanisms of action.

Ongoing trials of moderate-to-high doses of pure EPA ethyl ester will provide further information on the effects of these agents.^{10,36} These trials include the Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy–Statin and EPA (RESPECT-EPA; UMIN Clinical Trials Registry number, UMIN000012069), a secondary prevention outcomes trial involving statin-treated patients in Japan, and the Effect of Vascepa on Improving Coronary Atherosclerosis in People with High Triglycerides Taking Statin Therapy (EVAPORATE; ClinicalTrials.gov number, NCT02926027), which is examining changes in coronary plaque over 9 to 18 months.

Our trial has certain limitations. First, at the time the trial was designed, there was relatively little use of ezetimibe or data supporting its use.³⁷ However, subgroup analyses do not suggest a differential benefit for patients taking ezetimibe. Similarly, proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors were not available for the majority of the patients in the trial.³⁸ Second, if mineral oil in the placebo affected statin absorption in some patients, this might have contributed to differences in outcomes between the groups. However, the relatively small differences in LDL cholesterol levels between the groups would not be likely to explain the 25% lower risk observed with icosapent ethyl, and a post hoc analysis suggested a similar lower risk regardless of whether there was an increase in LDL cholesterol level among the patients in the placebo group. Although JELIS was designed as an open-label study that did not use a mineral oil placebo, it showed a 19% lower risk of ischemic events with statin therapy plus EPA than with statin therapy alone.

In conclusion, among patients with elevated triglyceride levels who were receiving statin therapy, the risk of major ischemic events, including cardiovascular death, was significantly lower with 2 g of icosapent ethyl twice daily (total daily dose, 4 g) than with placebo.

Supported by Amarin Pharma.

Dr. Bhatt reports receiving grant support from Amarin, Astra-Zeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, Sanofi Aventis, The Medicines Company, Roche, Pfizer, Forest Laboratories/AstraZeneca, Ischemix, Amgen, Lilly, Chiesi, Ironwood, Abbott, Regeneron, PhaseBio, Idorsia, and Synaptic, fees for serving on CME steering committees from WebMD, advisory board fees from Elsevier, fees for serving on the board of directors from TobeSoft, fees for serving on an executive steering committee (with payments from Baim Institute Clinical Research) and for editorial support service from Boehringer Ingelheim, and fees for serving on the operations committee, on the publications committee, on a steering committee (with payments from Population Health Research Institute), and as the USA co-national leader from Bayer, unfunded research collaborations with FlowCo, Novo Nordisk, Plx Pharma, Takeda, and Merck, and serving on advisory boards for Medscape Cardiology, Regado Biosciences, and Cardax and as site co-investigator for St. Jude Medical (now Abbott), Biotronik, Boston Scientific, and Svelte; Dr. Steg, receiving grant support and fees for serving on a steering committee from Bayer/Janssen, grant support and lecture fees from Merck, grant support, fees for serving as cochair of the ODYSSEY outcomes trial and as co-chair of the SCORED trial, consulting fees, and lecture fees from Sanofi, consulting fees and lecture fees from Amgen, consulting fees, lecture fees, and fees for serving on an event committee from Bristol-Myers Squibb, fees for serving on an executive steering committee from Boehringer Ingelheim, fees for serving on an event committee from Pfizer, consulting fees and fees for serving on an executive steering committee from Novartis, consulting fees from Regeneron and Lilly, consulting fees and fees for serving as co-chair of the THEMIS trial from AstraZeneca, and grant support and fees for serving as chair of the data and safety monitoring committee for the ATPCI trial and as chair of the CLARIFY registry from Servier; Dr. Brinton, receiving lecture fees from Boehringer, Janssen, Kaneka, and Novo Nordisk, consulting fees and lecture fees from Amarin, Amgen, AstraZeneca, Akcea, Kastle, Kowa, Merck, Sanofi, and Regeneron, and consulting fees from Arisaph, Denka-Seiken, Esperion, Medicure, Precision Biosciences, and PTS Diagnostics; Dr. Miller, receiving consulting fees from Amarin and Akcea; Dr. Jacobson, receiving consulting fees from AstraZeneca, Amgen, Novartis, Esperion, and Regeneron/Sanofi; Dr. Ketchum, Mr. Doyle, Dr. Juliano, Dr. Jiao, and Dr. Granowitz, being employed by and being a stock shareholder of Amarin Pharma; Dr. Tardif, receiving grant support from AstraZeneca, Esperion, and Ionis, grant support and consulting fees from DalCor, grant support and fees for serving as co-chairman of an executive committee from Pfizer, grant support and fees for serving on an executive committee from Sanofi, and grant support and consulting fees from Servier and holding a minor equity interest in DalCor and a patent (U.S. 9,909,178 B2) on Dalcetrapib for Therapeutic Use; and Dr. Ballantyne, receiving consulting fees from AstraZeneca, Eli Lilly, Matinas BioPharma, Merck, Boehringer Ingelheim, Novo Nordisk, Denka Seiken, and Gilead and grant support (paid to her institution) and consulting fees from Amarin, Amgen, Esperion, Novartis, Regeneron, Sanofi-Synthelabo, and Akcea. No other potential conflict of interest relevant to this article was reported.

A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

We thank the Amarin team members who are not authors of this article but who contributed to the success of the trial (Katelyn Diffin, M.B.A., and Angela Granger for clinical operations support; Ramakrishna Bhavanthula, M.S., Richard H. Iroudayassamy, Robert Wang, Ph.D., and Shin-Ru Wang, M.S., for data management and statistical support; and Joy Bronson, M.A., and Sephy Philip, R.Ph., Pharm.D., for editorial assistance that was limited to formatting and collation of coauthor comments) and the investigators, the study coordinators, and especially the patients who participated in REDUCE-IT.

N ENGLJ MED 380;1 NEJM.ORG JANUARY 3, 2019

21

The New England Journal of Medicine

Downloaded from nejm.org at Pfizer Information & Library Sciences on August 19, 2021. For personal use only. No other uses without permission.

REFERENCES

1. Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 2010;304:1350-7.

Nambi V, Bhatt DL. Primary prevention of atherosclerosis: time to take a selfie? J Am Coll Cardiol 2017;70:2992-4.
Vaduganathan M, Venkataramani AS, Bhatt DL. Moving toward global primordial prevention in cardiovascular disease: the heart of the matter. J Am Coll Cardiol 2015;66:1535-7.

 Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
Libby P. Triglycerides on the rise: should we swap seats on the seesaw? Eur Heart J 2015;36:774-6.

6. Klempfner R, Erez A, Sagit BZ, et al. Elevated triglyceride level is independently associated with increased all-cause mortality in patients with established coronary heart disease: twenty-two-year follow-up of the Bezafibrate Infarction Prevention Study and Registry. Circ Cardiovasc Oual Outcomes 2016;9:100-8.

7. Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S. Increased cardiovascular risk in hypertriglyceridemic patients with statin-controlled LDL cholesterol. J Clin Endocrinol Metab 2018;103: 3019-27.

8. Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S. Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol. Diabetes Obes Metab 2018 September 17 (Epub ahead of print).

9. Toth PP, Granowitz C, Hull M, Liassou D, Anderson A, Philip S. High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: a real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. J Am Heart Assoc 2018;7(15):e008740.

10. Ganda OP, Bhatt DL, Mason RP, Miller M, Boden WE. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol 2018; 72:330-43.

11. The ORIGIN Trial Investigators. n–3 Fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012;367:309-18.

12. The ASCEND Study Collaborative Group. Effects of n–3 fatty acid supplements in diabetes mellitus. N Engl J Med 2018;379:1540-50.

 Aung T, Halsey J, Kromhout D, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals. JAMA Cardiol 2018;3:225-34.
Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090-8.

15. Bhatt DL, Steg PG, Brinton EA, et al. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. Clin Cardiol 2017;40:138-48.

16. Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multicenter, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol 2011;108:682-90.

17. Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol 2012;110:984-92.

18. Bays HE, Ballantyne CM, Braeckman RA, Stirtan WG, Soni PN. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs 2013:13:37-46.

19. Nelson JR, Wani O, May HT, Budoff M. Potential benefits of eicosapentaenoic acid on atherosclerotic plaques. Vascul Pharmacol 2017;91:1-9.

20. Mason RP, Jacob RF, Shrivastava S, Sherratt SCR, Chattopadhyay A. Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes. Biochim Biophys Acta 2016;1858:3131-40. 21. Sherratt SCR, Mason RP. Eicosapentaenoic acid and docosahexaenoic acid have distinct membrane locations and lipid interactions as determined by X-ray diffraction. Chem Phys Lipids 2018;212:73-9. 22. Martin SS, Blaha MJ, Elshazly MB, et al. Comparison of a novel method vs the Friedewald equation for estimating lowdensity lipoprotein cholesterol levels from the standard lipid profile. JAMA 2013; 310:2061-8

23. Altman DG. Confidence intervals for the number needed to treat. BMJ 1998; 317:1309-12.

24. Daly LE. Confidence limits made easy: interval estimation using a substitution method. Am J Epidemiol 1998;147: 783-90.

25. Itakura H, Yokoyama M, Matsuzaki M, et al. Relationship between plasma fatty acid composition and coronary artery disease. J Atheroscler Thromb 2011; 18:99-107.

26. Bays HE, Ballantyne CM, Doyle RT Jr, Juliano RA, Philip S. Icosapent ethyl: eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies. Prostaglandins Other Lipid Mediat 2016;125:57-64.

27. Chang CH, Tseng PT, Chen NY, et al. Safety and tolerability of prescription omega-3 fatty acids: a systematic review and meta-analysis of randomized controlled trials. Prostaglandins Leukot Essent Fatty Acids 2018;129:1-12.

28. Nicholls SJ, Lincoff AM, Bash D, et al. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of highdensity lipoprotein cholesterol: rationale and design of the STRENGTH trial. Clin Cardiol 2018;41:1281-8.

29. Bhatt DL, Hulot JS, Moliterno DJ, Harrington RA. Antiplatelet and anticoagulation therapy for acute coronary syndromes. Circ Res 2014;114:1929-43.

30. Doi M, Nosaka K, Miyoshi T, et al. Early eicosapentaenoic acid treatment after percutaneous coronary intervention reduces acute inflammatory responses and ventricular arrhythmias in patients with acute myocardial infarction: a randomized, controlled study. Int J Cardiol 2014;176:577-82.

31. Watanabe T, Ando K, Daidoji H, et al. A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins. J Cardiol 2017; 70:537-44.

32. Borow KM, Nelson JR, Mason RP. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentae-noic acid (EPA) in atherosclerosis. Atherosclerosis 2015;242:357-66.

33. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017;377:1119-31.

34. Verma S, Leiter LA, Bhatt DL. CANTOS ushers in a new calculus of inflammasome targeting for vascular protection — and maybe more. Cell Metab 2017;26: 703-5.

35. Hong KN, Fuster V, Rosenson RS, Rosendorff C, Bhatt DL. How low to go with glucose, cholesterol, and blood pressure in primary prevention of CVD. J Am Coll Cardiol 2017;70:2171-85.

36. Budoff M, Brent Muhlestein J, Le VT, May HT, Roy S, Nelson JR. Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: rationale and design of the EVAPORATE study. Clin Cardiol 2018;41: 13-9.

37. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387-97.

38. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018 November 7 (Epub ahead of print).

Copyright © 2018 Massachusetts Medical Society.

N ENGLJ MED 380;1 NEJM.ORG JANUARY 3, 2019

The New England Journal of Medicine

Downloaded from nejm.org at Pfizer Information & Library Sciences on August 19, 2021. For personal use only. No other uses without permission.